Characteristic | Treatment-naïve |
---|---|
(N = 39) | |
Mean (SD) age, years | 68.4 (12.6) |
Range | 39–88 |
Sex, n (%) | |
Female | 21 (53.8) |
Male | 18 (46.2) |
Race/Ethnicity, n (%) | |
White | 20 (51.3) |
Black, Asian, or other | 3 (7.7) |
Not recorded in chart | 16 (41.0) |
Diagnosis, n (%) | |
BRVO | 18 (46.2) |
CRVO | 21 (53.8) |
Mean (SD) duration of macular edema, months | 4.9 (16.7) |
Median | 1.2 |
Range | 0 to 105 |
Prior treatment for complications of retinal vein occlusion, n (%) | 0 (0) |
Glaucoma or ocular hypertension at baseline, n (%) | |
Yes | 6 (15.4) |
No | 23 (59.0) |
Not recorded in chart | 10 (25.6) |
Using IOP-lowering medication at baseline, n (%) | 3 (7.7) |
History of IOP response to steroid, n (%) | |
Yes | 1 (2.6) |
No | 24 (61.5) |
Not recorded in chart | 14 (35.9) |
Lens status, n (%) | |
Phakic | 23 (59.0) |
Pseudophakic | 15 (38.5) |
Not recorded | 1 (2.6) |
Mean (SD) BCVA, lines | 8.5 (5.1) |
Snellen | 20/125 |
Mean (SD) central retinal thickness, μm | 550 (207) |